Categories
Multiple Myeloma
Amgen (NASDAQ:AMGN) Rating Increased to Sell at BidaskClub
Amgen (NASDAQ:AMGN) Rating Increased to Sell at BidaskClub Amgen (NASDAQ:AMGN) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday, BidAskClub reports. Several other research analysts have also recently weighed in on the company. Truist upgraded Amgen from […]
Read More